Article Text

PDF

Maintenance of sinus rhythm after DC reversion of atrial fibrillation
  1. Edward Byrne-Quinn1,
  2. A. J. Wing2
  1. Cardiac Department, St. Thomas' Hospital, London S.E. 1

    A double-blind controlled trial of long-acting quinidine bisulphate

    Abstract

    Ninety-two patients were entered in a double-blind controlled trial of long-acting quinidine bisulphate for the maintenance of sinus rhythm following DC reversion of atrial fibrillation. By random selection two statistically comparable groups of patients were obtained, a control group being given a placebo and a treated group quinidine bisulphate 1·5 g. per day in two 12-hourly doses. Thirty-seven patients were followed up in the control group and twenty-eight patients in the treated group. The maintenance of sinus rhythm in the treated group was significantly longer than in the control group, especially during the first three months. The mean serum quinidine level in the treated group was 2·2±0·3 (SEM) mg. per litre. There was one death among the patients treated with quinidine, which may have been due to quinidine toxicity caused by a high serum quinidine level.

    Statistics from Altmetric.com

    Footnotes

    • 1 Present address: Cardiovascular Pulmonary Research Laboratory, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colorado 80220, U.S.A.

    • 2 Requests for reprints should be addressed to A.J.W. at St. Thomas' Hospital.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.